Clinical Efficacy and Safety of Bevacizumab, Apatinib, and Recombinant Human Endothelial Inhibitor in the Treatment of Advanced Gastric Cancer

Table 3

Comparison of the incidence of adverse reactions among the four groups of patients (n (%)).

Groups	n	Thrombocytopenia		Cardiovascular toxicity		Leukopenia		Hemoglobin reduction		Abnormal liver and kidney functions		Nausea and vomiting
		I-II	III-IV	I-II	III-IV	I-II	III-IV	I-II	III-IV	I-II	III-IV	I-II	III-IV
Control group	51	20	17	15	14	19	14	18	10	18	12	22	11
Study group I	51	21	15	15	13	21	17	15	11	19	17	25	13
Study group II	51	20	14	14	11	17	17	14	13	18	16	23	12
Study group III	51	23	16	16	16	19	18	17	16	20	16	26	14